Soo Yeon An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Soo Yeon An has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Jin-Ok Jeong
Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
5 shared publications - Do-Yoon Kang
Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (S.-B.W., J.-M.A., D.-Y.K., J.H.K., H.S.P., S.Y.A., K.-W.S., S.H.L., D.-W.P., S.-J.P.).
4 shared publications - Duk-Woo Park
Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4 shared publications - Seung Han Lee
Division of Cardiology, Department of Internal Medicine University of Ulsan College of Medicine, Asan Medical Center Seoul Korea
4 shared publications - Han Su Park
Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (S.-B.W., J.-M.A., D.-Y.K., J.H.K., H.S.P., S.Y.A., K.-W.S., S.H.L., D.-W.P., S.-J.P.).
3 shared publications - Ju Hyeon Kim
Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (S.-B.W., J.-M.A., D.-Y.K., J.H.K., H.S.P., S.Y.A., K.-W.S., S.H.L., D.-W.P., S.-J.P.).
3 shared publications
Latest Publications
- 15 November 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Twelve‐Year Follow‐Up Outcomes After Percutaneous Coronary Intervention for Coronary Chronic Total Occlusion
Background: Over decades of advancement, percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) has achieved high success rates and acceptable safety outcomes. However, the survival benefits of CTO‐PCI are still debated. Aims: To understand the clinical benefit of CTO‐PCI better, we present the 12‐year follow‐up results of a prospective CTO registry study, with the aim of describing the clinical course according to patients' risk characteristics. Methods: Between March 2003 and February 2015, 1219 consecutive patients with CTO of native coronary vessels requiring PCI were enrolled. Among them, CTO‐PCI was successful in 1047 patients (85.9%). The primary outcome of this study was all‐cause death at maximum available follow‐up between patients with successful and failed CTO recanalization. Results: During the median follow‐up of 12.1 years, all‐cause death was not significant difference between the CTO‐PCI success group and the CTO‐PCI failure group (15.6% vs. 18.0% at 12 years, p = 0.69). In multivariable analysis for the primary outcome, the failure of CTO‐PCI was not an independent risk factor for all‐cause death (adjusted hazard ratio 0.842; p = 0.302) or myocardial infarction (adjusted hazard ratio 0.667; p = 0.345). Independent predictors of all‐cause death included diabetes, previous history of myocardial infarction, heart failure, or chronic kidney disease. Conclusion: Compared with successful PCI for CTO, failed PCI for CTO was not associated with a higher long‐term risk of all‐cause death or myocardial infarction. Adverse clinical characteristics were an independent predictor of adverse clinical outcomes.
- 15 November 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Twelve‐Year Follow‐Up Outcomes After Percutaneous Coronary Intervention for Coronary Chronic Total Occlusion
Background: Over decades of advancement, percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) has achieved high success rates and acceptable safety outcomes. However, the survival benefits of CTO‐PCI are still debated. Aims: To understand the clinical benefit of CTO‐PCI better, we present the 12‐year follow‐up results of a prospective CTO registry study, with the aim of describing the clinical course according to patients' risk characteristics. Methods: Between March 2003 and February 2015, 1219 consecutive patients with CTO of native coronary vessels requiring PCI were enrolled. Among them, CTO‐PCI was successful in 1047 patients (85.9%). The primary outcome of this study was all‐cause death at maximum available follow‐up between patients with successful and failed CTO recanalization. Results: During the median follow‐up of 12.1 years, all‐cause death was not significant difference between the CTO‐PCI success group and the CTO‐PCI failure group (15.6% vs. 18.0% at 12 years, p = 0.69). In multivariable analysis for the primary outcome, the failure of CTO‐PCI was not an independent risk factor for all‐cause death (adjusted hazard ratio 0.842; p = 0.302) or myocardial infarction (adjusted hazard ratio 0.667; p = 0.345). Independent predictors of all‐cause death included diabetes, previous history of myocardial infarction, heart failure, or chronic kidney disease. Conclusion: Compared with successful PCI for CTO, failed PCI for CTO was not associated with a higher long‐term risk of all‐cause death or myocardial infarction. Adverse clinical characteristics were an independent predictor of adverse clinical outcomes.
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
Lipid Burden and Efficacy of Preventive PCI of Vulnerable Atherosclerotic Coronary Plaques: Post Hoc Analysis From the PREVENT Trial
BACKGROUND: Preventive percutaneous coronary intervention (PCI) of non–flow-limiting lesions (fractional flow reserve >0.80) that are high-risk plaques has emerged as a potential strategy to reduce cardiac events. However, identifying which lesions derive the greatest benefit from preventive PCI compared with optimal medical therapy alone remains challenging. This post hoc analysis evaluates the role of the near-infrared spectroscopy–derived lipid core burden index in identifying high-risk plaques that may benefit from preventive PCI. METHODS: Among the 1606 patients enrolled in the PREVENT trial (Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque) from September 2015 to September 2021, an investigator-initiated, multicenter, open-label, randomized controlled trial, this post hoc analysis included 598 patients (mean age, 64.1±8.8 years; 27.9% women) comprising 632 lesions with a plaque burden >70% and a minimal lumen area 315. The primary outcome was a composite of death from cardiac causes, target-vessel myocardial infarction, ischemia-driven target-vessel revascularization, or hospitalization for unstable or progressive angina. RESULTS: LRPs were present in 223 patients (37.3%) with 234 lesions. During median follow-up of 5.6 years, primary outcome events occurred more frequently in patients with LRPs than in those with non-LRPs (12.5% versus 4.7%; unadjusted hazard ratio, 2.08; 95% CI, 1.03–4.19; P =0.039) in the overall population. Within the LRP group, preventive PCI was associated with a lower risk of the primary outcome compared with optimal medical therapy alone (7.3% vs. 17.6%; adjusted hazard ratio, 0.23; 95% CI, 0.13–0.41; P P =0.97). A significant interaction was found between treatment strategy and the presence of LRP ( P interaction <0.001). CONCLUSIONS: In this post hoc analysis of the PREVENT trial, preventive PCI was associated with a lower risk of the primary composite outcome in patients with near-infrared spectroscopy–defined LRPs, whereas no significant association was observed in those with non-LRPs despite their large plaque burden and small minimal lumen area. These findings suggest the importance of plaque composition, beyond morphological severity alone, in guiding preventive PCI. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02316886.
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
Lipid Burden and Efficacy of Preventive PCI of Vulnerable Atherosclerotic Coronary Plaques: Post Hoc Analysis From the PREVENT Trial
BACKGROUND: Preventive percutaneous coronary intervention (PCI) of non–flow-limiting lesions (fractional flow reserve >0.80) that are high-risk plaques has emerged as a potential strategy to reduce cardiac events. However, identifying which lesions derive the greatest benefit from preventive PCI compared with optimal medical therapy alone remains challenging. This post hoc analysis evaluates the role of the near-infrared spectroscopy–derived lipid core burden index in identifying high-risk plaques that may benefit from preventive PCI. METHODS: Among the 1606 patients enrolled in the PREVENT trial (Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque) from September 2015 to September 2021, an investigator-initiated, multicenter, open-label, randomized controlled trial, this post hoc analysis included 598 patients (mean age, 64.1±8.8 years; 27.9% women) comprising 632 lesions with a plaque burden >70% and a minimal lumen area 315. The primary outcome was a composite of death from cardiac causes, target-vessel myocardial infarction, ischemia-driven target-vessel revascularization, or hospitalization for unstable or progressive angina. RESULTS: LRPs were present in 223 patients (37.3%) with 234 lesions. During median follow-up of 5.6 years, primary outcome events occurred more frequently in patients with LRPs than in those with non-LRPs (12.5% versus 4.7%; unadjusted hazard ratio, 2.08; 95% CI, 1.03–4.19; P =0.039) in the overall population. Within the LRP group, preventive PCI was associated with a lower risk of the primary outcome compared with optimal medical therapy alone (7.3% vs. 17.6%; adjusted hazard ratio, 0.23; 95% CI, 0.13–0.41; P P =0.97). A significant interaction was found between treatment strategy and the presence of LRP ( P interaction <0.001). CONCLUSIONS: In this post hoc analysis of the PREVENT trial, preventive PCI was associated with a lower risk of the primary composite outcome in patients with near-infrared spectroscopy–defined LRPs, whereas no significant association was observed in those with non-LRPs despite their large plaque burden and small minimal lumen area. These findings suggest the importance of plaque composition, beyond morphological severity alone, in guiding preventive PCI. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02316886.
- Open Access
- 3 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial
Aims: The appropriate antithrombotic regimen for diabetic patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) who are at high atherothrombotic risk remains uncertain. We evaluated whether the effects of different antithrombotic strategies differ according to diabetes status. Methods and results: The EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) was a randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with AF and stable CAD. The primary outcome was a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant non-major bleeding at 12 months. Among 1040 randomized patients, 421 (40.5%) had diabetes. There were no differences in the incidence of the primary outcome between diabetic and non-diabetic patients [9.7% vs. 11.6%; hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.56-1.20; P = 0.30]. The incidence of the primary outcome at 12 months was significantly lower with edoxaban monotherapy than with dual antithrombotic therapy in both diabetic (6.3% vs. 13.7%; HR 0.44; 95% CI 0.23-0.83; P = 0.01) and non-diabetic patients (6.7% vs. 16.3%; HR 0.39; 95% CI 0.23-0.65; P < 0.001), with no significant interaction between diabetic status and randomized treatment strategy (P for interaction = 0.78). Conclusion: The risk of primary outcome was similar between diabetic and non-diabetic patients with AF and CAD. Irrespective of diabetes status, edoxaban monotherapy led to a lower risk of a primary outcome at 12 months than dual antithrombotic therapy. Clinical trial registration: EPIC-CAD ClinicalTrials.gov number: NCT03718559.
- 3 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Open AccessEdoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial
Aims: The appropriate antithrombotic regimen for diabetic patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) who are at high atherothrombotic risk remains uncertain. We evaluated whether the effects of different antithrombotic strategies differ according to diabetes status. Methods and results: The EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) was a randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with AF and stable CAD. The primary outcome was a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant non-major bleeding at 12 months. Among 1040 randomized patients, 421 (40.5%) had diabetes. There were no differences in the incidence of the primary outcome between diabetic and non-diabetic patients [9.7% vs. 11.6%; hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.56-1.20; P = 0.30]. The incidence of the primary outcome at 12 months was significantly lower with edoxaban monotherapy than with dual antithrombotic therapy in both diabetic (6.3% vs. 13.7%; HR 0.44; 95% CI 0.23-0.83; P = 0.01) and non-diabetic patients (6.7% vs. 16.3%; HR 0.39; 95% CI 0.23-0.65; P < 0.001), with no significant interaction between diabetic status and randomized treatment strategy (P for interaction = 0.78). Conclusion: The risk of primary outcome was similar between diabetic and non-diabetic patients with AF and CAD. Irrespective of diabetes status, edoxaban monotherapy led to a lower risk of a primary outcome at 12 months than dual antithrombotic therapy. Clinical trial registration: EPIC-CAD ClinicalTrials.gov number: NCT03718559.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e016014
Transcatheter Aortic Valve Replacement for Severe Bicuspid Aortic Valve Stenosis
Surgical aortic valve (AV) replacement has been the standard treatment for patients with severe symptomatic degenerative AV stenosis (AS). In recent years, transcatheter AV replacement has emerged as an established alternative in selected patient populations, supported by robust evidence in tricuspid AS. However, there has been limited evaluation of transcatheter AV replacement in bicuspid AV AS. Recently, several observational studies have demonstrated the feasibility and safety of transcatheter AV replacement in bicuspid AV AS, and the use of newer-generation devices has shown encouraging outcomes. However, the incidence of procedural complications such as paravalvular regurgitation, permanent pacemaker implantation, and aortic root injury was more frequent in patients with bicuspid AV AS compared with tricuspid AS. We review the clinical evidence of transcatheter AV replacement for bicuspid AV AS and suggest the appropriate criteria for patient and device selection, implantation techniques, and further management.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e016014
Transcatheter Aortic Valve Replacement for Severe Bicuspid Aortic Valve Stenosis
Surgical aortic valve (AV) replacement has been the standard treatment for patients with severe symptomatic degenerative AV stenosis (AS). In recent years, transcatheter AV replacement has emerged as an established alternative in selected patient populations, supported by robust evidence in tricuspid AS. However, there has been limited evaluation of transcatheter AV replacement in bicuspid AV AS. Recently, several observational studies have demonstrated the feasibility and safety of transcatheter AV replacement in bicuspid AV AS, and the use of newer-generation devices has shown encouraging outcomes. However, the incidence of procedural complications such as paravalvular regurgitation, permanent pacemaker implantation, and aortic root injury was more frequent in patients with bicuspid AV AS compared with tricuspid AS. We review the clinical evidence of transcatheter AV replacement for bicuspid AV AS and suggest the appropriate criteria for patient and device selection, implantation techniques, and further management.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (3) , e66
Erratum: Correction of Funding in the Article “Prognostic Significance of Fatty Liver Index for the Development of Hypertension and Cardiovascular Events in Populations With Suboptimal Blood Pressure”
Bok Y, et al. J Korean Med Sci. 2026 Jan;41(3):e66. https://doi.org/10.3346/jkms.2026.41.e66
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (3) , e66
Open AccessErratum: Correction of Funding in the Article “Prognostic Significance of Fatty Liver Index for the Development of Hypertension and Cardiovascular Events in Populations With Suboptimal Blood Pressure”
Bok Y, et al. J Korean Med Sci. 2026 Jan;41(3):e66. https://doi.org/10.3346/jkms.2026.41.e66
- Open Access
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (12) , 1055-1076
Management of Coronary Artery Disease in Patients With Severe Aortic Stenosis
Kim JH, et al. Korean Circ J. 2025 Aug;55:e127. https://doi.org/10.4070/kcj.2025.0268
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (12) , 1055-1076
Open AccessManagement of Coronary Artery Disease in Patients With Severe Aortic Stenosis
Kim JH, et al. Korean Circ J. 2025 Aug;55:e127. https://doi.org/10.4070/kcj.2025.0268
- Open Access
- 1 January 2025
- Published by XMLink in International Journal of Heart Failure
- Vol. 7 (2) , 110-115
Poor Outcome of the p.Ser43Asn TTR Variant Causing Hereditary Transthyretin Amyloidosis in Korea
An SY, et al. Int J Heart Fail. 2025 Apr;7(2):110-115. https://doi.org/10.36628/ijhf.2024.0075
- 1 January 2025
- Published by XMLink in International Journal of Heart Failure
- Vol. 7 (2) , 110-115
Open AccessPoor Outcome of the p.Ser43Asn TTR Variant Causing Hereditary Transthyretin Amyloidosis in Korea
An SY, et al. Int J Heart Fail. 2025 Apr;7(2):110-115. https://doi.org/10.36628/ijhf.2024.0075
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (26) , e135
Prognostic Significance of Fatty Liver Index for the Development of Hypertension and Cardiovascular Events in Populations With Suboptimal Blood Pressure
Bok Y, et al. J Korean Med Sci. 2025 Apr;40(26):e135. https://doi.org/10.3346/jkms.2025.40.e135
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (26) , e135
Open AccessPrognostic Significance of Fatty Liver Index for the Development of Hypertension and Cardiovascular Events in Populations With Suboptimal Blood Pressure
Bok Y, et al. J Korean Med Sci. 2025 Apr;40(26):e135. https://doi.org/10.3346/jkms.2025.40.e135
- Open Access
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (4) , 189-200
The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention
Song PS, et al. Korean Circ J. 2024 Apr;54(4):189-200. https://doi.org/10.4070/kcj.2023.0268
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (4) , 189-200
Open AccessThe Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention
Song PS, et al. Korean Circ J. 2024 Apr;54(4):189-200. https://doi.org/10.4070/kcj.2023.0268
- Open Access
- 13 August 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (16) , 2666
Rapidly Progressive Metastatic Angiosarcoma of the Heart: A Case Report
Cardiac angiosarcoma is a rare, malignant neoplasm affecting the heart. We present the clinical history of a 40-year-old patient diagnosed with metastatic angiosarcoma of the heart. The patient complained of shortness of breath, and a cardiac computed tomography scan revealed a mass in the right atrium and pericardial effusion. Transthoracic and transesophageal echocardiography provided detailed anatomical and functional information, and cardiac magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography/computed tomography were used to assess distant metastasis and characterize the mass in detail. Early differential diagnosis and comprehensive evaluation of a cardiac mass are vital for determining appropriate treatment strategies to improve patient outcomes. The pathological results from the endocardial biopsy confirmed the diagnosis of primary angiosarcoma. The patient underwent surgical resection of the right atrial mass but died within one month because of the locally advanced nature of the angiosarcoma and its rapid progression. The patient’s medical journey sheds light on the challenges associated with diagnosing and treating this rare condition, particularly the rapid progression of its cardiac manifestations.
- 13 August 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (16) , 2666
Open AccessRapidly Progressive Metastatic Angiosarcoma of the Heart: A Case Report
Cardiac angiosarcoma is a rare, malignant neoplasm affecting the heart. We present the clinical history of a 40-year-old patient diagnosed with metastatic angiosarcoma of the heart. The patient complained of shortness of breath, and a cardiac computed tomography scan revealed a mass in the right atrium and pericardial effusion. Transthoracic and transesophageal echocardiography provided detailed anatomical and functional information, and cardiac magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography/computed tomography were used to assess distant metastasis and characterize the mass in detail. Early differential diagnosis and comprehensive evaluation of a cardiac mass are vital for determining appropriate treatment strategies to improve patient outcomes. The pathological results from the endocardial biopsy confirmed the diagnosis of primary angiosarcoma. The patient underwent surgical resection of the right atrial mass but died within one month because of the locally advanced nature of the angiosarcoma and its rapid progression. The patient’s medical journey sheds light on the challenges associated with diagnosing and treating this rare condition, particularly the rapid progression of its cardiac manifestations.